EGFR and colorectal carcinoma: Sanchez-Martin FJ et al. have evaluated the efficacy of SYM004, in vitro and in vivo, in cetuximab-resistant CRC models and have found that SYM004 is a valid strategy to treat CRC tumors harboring EGFR ECD mutations [20].